TL;DR
Comments on the FDA's first genome-editing off-target safety guidance close July 14; the four listed gene-editing firms have said nothing.
MSM Perspective
Endpoints and FDA trade press frame the guidance as a technical step inside the individualized-therapy framework.
X Perspective
Scientists on X read the industry silence as pricing in near-total alignment with the draft.
The FDA's April 14 draft guidance "Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing" appeared in the Federal Register on April 15 under docket FDA-2026-D-1255, with a 90-day comment period that closes July 14. [1] The document is the first FDA framework specifically covering how sponsors should use next-generation sequencing to assess off-target editing and loss of genome integrity in CRISPR and related therapies. [2] It applies to both ex vivo products and in vivo products where editing happens inside the patient. [2]
The paper's Saturday piece called this the FDA's first framework for CRISPR safety. The comment period is the test of the framework's reception. Four of the listed large CRISPR developers — Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics and Vertex — have posted no public statements on the draft through Sunday morning. That silence is itself the Sunday data point. Industry silence on a first-of-its-kind off-target safety framework usually means one of two things: acceptance of the draft's substance, or a coordinated response deferred for a longer horizon. The 90-day clock narrows that horizon.
FDA Commissioner Marty Makary framed the document as aligned with the agency's February launch of its individualized-therapy framework for ultra-rare diseases. "This guidance provides sponsors with clear, scientifically-grounded recommendations for evaluating off-target editing risks using state-of-the-art sequencing technologies," Makary said. [2] The Center for Biologics Evaluation and Research Director Vinay Prasad called NGS a tool that "not only detects off-target editing and assesses chromosomal integrity; it also requires science-based recommendations for its use." [2]
The draft builds on the FDA's January 2024 guidance and targets nonclinical studies supporting Investigational New Drug applications and Biologics License Applications. [1] Sponsors are encouraged to engage early through INTERACT and pre-IND meetings. [2] What arrives at regulations.gov before July 14 will shape how the United States polices its first approvals.
-- KENJI NAKAMURA, Tokyo
Sources & X Posts
News Sources